Related Experiment Video
Updated: Jul 22, 2026
06:02
Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model
Published on: July 26, 2011
Histocompatibility antigens in Alzheimer's disease. A preliminary study
European Neurology
|January 1, 1981
Summary
This preliminary study suggests a link between specific human leukocyte antigens (HLAs) and early-onset Alzheimer's disease (AD). Antigen A2 may be more common in AD patients under 60, while A1 and A3 frequencies differ in later-onset cases.
Area of Science:
- Immunogenetics
- Neurology
- Gerontology
Background:
- Alzheimer's disease (AD) is a progressive neurodegenerative disorder.
- Genetic factors are implicated in AD pathogenesis.
- Human Leukocyte Antigen (HLA) systems play a role in immune response and have been investigated in various diseases.
Purpose of the Study:
- To investigate the potential association between HLA antigen distribution and the age of onset in Alzheimer's disease.
- To explore differences in HLA antigen frequencies between early-onset and late-onset AD patients and a control population.
Main Methods:
- A preliminary case-control study design.
- Analysis of HLA antigen frequencies (A locus and B locus) in patients with Alzheimer's disease.
- Comparison of antigen frequencies with a local population.
Main Results:
- An apparent excess of antigen A2 was observed in Alzheimer's disease patients with onset before age 60.
- Patients with Alzheimer's disease onset after age 64 showed different frequencies of antigens A1 and A3 compared to the local population.
- No abnormalities were found in the distribution of B locus antigens.
Conclusions:
- Specific HLA antigen profiles may be associated with different age-of-onset patterns in Alzheimer's disease.
- Further research is warranted to confirm these preliminary findings and elucidate the underlying mechanisms.
More Related Videos
09:33Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
04:22Biomarker Identification for Gender Specificity of Alzheimer's Disease Based on the Glial Transcriptome Profiles
Published on: May 20, 2024
Related Concept Videos
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...